Znfpc Spilhaus Center
Harare, Zimbabwe
NCT Number: NCT01956370
The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe
Looking for future studies?
Notify Me18 year–30 year
Male
Interventional
Phase 2
Harare, Zimbabwe
Models show that to have the highest impact on the HIV epidemic, circumcision of up to 80% of men in high prevalence countries, where MC rates are low, needs to be achieved (UNAIDS 2009; Manicaland HIV/STD Prevention Project, 2008; Bollinger, et al, 2009). Hallett and colleagues in 2008 showed that for Zimbabwe specifically, HIV incidence could be reduced between 25% to 35% if about 50% of men are circumcised. All modelings conducted show that MC programs must be part of a comprehensive HIV prevention package as MC alone will not tip the HIV epidemic into a terminal decline.
The PrePex Device offers hope for rapid scale up of adult male circumcision in resource limited settings.
Once the safety and efficacy have been established, it is important to conduct operations research to determine how best to implement both device and surgical circumcisions in the national program. Thus, the Zimbabwe MOHCW is planning a three phase trial in order to determine the safety of the PrePexTM device, its performance and the ease of use in an implementation roll out.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
Other names: The PrePex Device, PrePex, PrePex™
The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
Time frame: 9 weeks
To compare the total operative time of the PrePex Device circumcision procedure versus the total operative time of surgical circumcision procedure.
Time frame: 9 weeks
Expectations of men regarding the procedure using questionnaires
Time frame: 9 weeks
Satisfaction with procedure using questionnaires and evaluations
Time frame: 9 weeks
Attitudes towards procedure using questionnaires
Time frame: 9 weeks
Sharing information with family and friends by evaluating weather subjects would recommend the procedure to others using questionnaires
Time frame: 9 weeks
Perception of norms using questionnaires
Time frame: 9 weeks
Sexual relations, performance, satisfaction using questionnaires
Time frame: 9 weeks
Sexual behavior using questionnaires. Inquiring of sexual behavior before and after the circumcision, etc.
Time frame: 9 weeks
Sexual partner's attitudes using questionnaires and investigating the partner's behavior change as a result of her partner's circumcision.
Time frame: 9 weeks
Effect on daily activities using questionnaires. Inquiring and finding out if the MC procedure caused any missing of working days.
Time frame: 9 weeks
Evaluating the cost of PrePex circumcision procedure when taking into account the following parameters:
i. PrePex Procedure time and the resulting cost of provider's time ii. Cost of staff time for follow-up visits iii. Cost of equipment and supplies needed for the circumcision procedure
Time frame: 9 weeks
Cost-effectiveness
Ministry of Health and Child Welfare, Zimbabwe
Other
Phase II - Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult Male Circumcision Programs in Zimbabwe (Comparative Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06125509
HIV
Tallahassee, Florida, United States
View Trial DetailsNCT07225894
Behavior, HIV
Kisumu, Kisumu County, Kenya
View Trial DetailsNCT02447159
Behavior, Blood-Borne Infections
Eket, Akwa Ibom State, Nigeria
View Trial DetailsNCT03734393
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial Details